Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin
NCT ID: NCT01628445
Last Updated: 2016-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
52 participants
INTERVENTIONAL
2012-08-31
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
NCT01620489
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
NCT01624259
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
NCT02098395
The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes
NCT06408532
A Study of LY2599506 in Patients With Type 2 Diabetes
NCT01024244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
liraglutide
liraglutide 1.8 mg injected once daily
liraglutide
liraglutide titrated to 1.8 mg sc daily
Placebo injection
placebo injection
placebo injected sc daily volume equal to active comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
liraglutide
liraglutide titrated to 1.8 mg sc daily
placebo injection
placebo injected sc daily volume equal to active comparator
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI≤45 kg/m2
* A1c ≥7.5% and ≤10.5%
Exclusion Criteria
* symptoms of poorly controlled diabetes
* eGFR \<50 ml/min/1.73m2
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
University of Manitoba
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Vincent Woo
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vincent C Woo, MD FRCPC
Role: PRINCIPAL_INVESTIGATOR
University of Mantioba
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Winnipeg Regional Health Authority Health Sciences Centre Winnipeg Diabetes Research Group
Winnipeg, Manitoba, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1126-3937
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.